Logo image of MBIO

MUSTANG BIO INC (MBIO) Stock Fundamental Analysis

NASDAQ:MBIO - US62818Q3020 - Common Stock

1.65 USD
-0.04 (-2.37%)
Last: 8/22/2025, 7:25:05 PM
Fundamental Rating

2

MBIO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 549 industry peers in the Biotechnology industry. While MBIO seems to be doing ok healthwise, there are quite some concerns on its profitability. MBIO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MBIO has reported negative net income.
MBIO had a negative operating cash flow in the past year.
In the past 5 years MBIO always reported negative net income.
In the past 5 years MBIO always reported negative operating cash flow.
MBIO Yearly Net Income VS EBIT VS OCF VS FCFMBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

MBIO has a better Return On Assets (-25.15%) than 71.95% of its industry peers.
MBIO has a Return On Equity of -113.15%. This is comparable to the rest of the industry: MBIO outperforms 42.44% of its industry peers.
Industry RankSector Rank
ROA -25.15%
ROE -113.15%
ROIC N/A
ROA(3y)-181.55%
ROA(5y)-130.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MBIO Yearly ROA, ROE, ROICMBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

1.3 Margins

MBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBIO Yearly Profit, Operating, Gross MarginsMBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for MBIO has been reduced compared to 1 year ago.
Compared to 5 years ago, MBIO has less shares outstanding
MBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MBIO Yearly Shares OutstandingMBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
MBIO Yearly Total Debt VS Total AssetsMBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -42.51, we must say that MBIO is in the distress zone and has some risk of bankruptcy.
MBIO has a Altman-Z score of -42.51. This is amonst the worse of the industry: MBIO underperforms 90.53% of its industry peers.
MBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -42.51
ROIC/WACCN/A
WACCN/A
MBIO Yearly LT Debt VS Equity VS FCFMBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 1.30 indicates that MBIO should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.30, MBIO is doing worse than 84.15% of the companies in the same industry.
A Quick Ratio of 1.30 indicates that MBIO should not have too much problems paying its short term obligations.
MBIO has a worse Quick ratio (1.30) than 83.06% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 1.3
MBIO Yearly Current Assets VS Current LiabilitesMBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

MBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.87%, which is quite impressive.
EPS 1Y (TTM)97.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 15.53% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.62%
EPS Next 2Y39.11%
EPS Next 3Y25.28%
EPS Next 5Y15.53%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MBIO Yearly Revenue VS EstimatesMBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
MBIO Yearly EPS VS EstimatesMBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -200 -400 -600 -800

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MBIO Price Earnings VS Forward Price EarningsMBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBIO Per share dataMBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as MBIO's earnings are expected to grow with 25.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.11%
EPS Next 3Y25.28%

More info and screens

0

5. Dividend

5.1 Amount

MBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MUSTANG BIO INC

NASDAQ:MBIO (8/22/2025, 7:25:05 PM)

1.65

-0.04 (-2.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11
Earnings (Next)11-06 2025-11-06
Inst Owners3.22%
Inst Owner Change-34.87%
Ins Owners0.09%
Ins Owner Change13.03%
Market Cap11.95M
Analysts82.86
Price TargetN/A
Short Float %2.25%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.98
P/tB 3.98
EV/EBITDA N/A
EPS(TTM)-3.09
EYN/A
EPS(NY)-2.02
Fwd EYN/A
FCF(TTM)-0.84
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS0
BVpS0.41
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.15%
ROE -113.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-181.55%
ROA(5y)-130.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.3
Quick Ratio 1.3
Altman-Z -42.51
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)34.11%
Cap/Depr(5y)80.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.93%
EPS Next Y42.62%
EPS Next 2Y39.11%
EPS Next 3Y25.28%
EPS Next 5Y15.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y91.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.88%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y90.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y90.12%
OCF growth 3YN/A
OCF growth 5YN/A